Obesity / Weight management

Weight change – an example

Before

AI-generated©

After

AI-generated©

Schematic illustration, not a promised treatment outcome. The course and extent of weight change vary from person to person.

Treatment at a glance

Which medicines are we talking about?

Ozempic (semaglutide) is approved for the treatment of insufficiently controlled type 2 diabetes in adults, alongside diet and exercise. It is not approved for weight loss alone.

Wegovy (semaglutide) is approved for weight management when the eligibility criteria are met.

Mounjaro (tirzepatide) is approved both for the treatment of type 2 diabetes and, under certain conditions, for weight management in adults. Tirzepatide acts on the receptors of the two gut hormones GIP and GLP-1.

How do they work?

• They increase the feeling of fullness by acting on the brain.
• Stomach emptying is slowed down, so you feel full for longer.
• Cravings for high-calorie foods decrease.

What should you keep in mind?

• Medical support
• A balanced diet
• Regular physical activity
• Drink enough fluids

The images are illustrations and do not show treatment outcomes in real people. This information does not replace individual medical advice; treatment is tailored to your situation.

These medicines can cause side effects, particularly nausea, vomiting and diarrhoea. Abdominal pain and constipation are also common with tirzepatide; when combined with insulin or sulfonylureas, the risk of hypoglycaemia may increase. Benefits, risks and contraindications are assessed individually before prescribing. Full details are provided in the linked EMA information and the relevant package leaflet.

Semaglutide acts on the GLP-1 receptor; tirzepatide acts on GIP and GLP-1 receptors. Your doctor will assess which treatment is suitable for you.

Marketing authorisation information (EMA): Ozempic · Wegovy · Mounjaro